Scarica l'app Stockscreener
21.07
5.03%
1.01
Dopo l'orario di chiusura:
21.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$20.06
Aprire:
$20.575
Volume 24 ore:
114.63K
Relative Volume:
0.59
Capitalizzazione di mercato:
$376.57M
Reddito:
$116.88M
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-150.50
EPS:
-0.14
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+9.28%
1M Prestazione:
+11.81%
6M Prestazione:
-4.83%
1 anno Prestazione:
+100.09%
Intervallo 1D:
$20.57
$21.13
Intervallo di 1 settimana:
$18.66
$21.13
Portata 52W:
$8.61
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Confronta RIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
21.07 | 358.52M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks
What analysts say about Rigel Pharmaceuticals Inc. stockDynamic investment opportunities - jammulinksnews.com
Is Rigel Pharmaceuticals Inc. a good long term investmentOutstanding yields - jammulinksnews.com
(RIGL) Proactive Strategies - news.stocktradersdaily.com
Rigel Pharmaceuticals Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What drives Rigel Pharmaceuticals Inc. stock priceTriple-digit returns - jammulinksnews.com
What makes Rigel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - newser.com
Why Rigel Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser
H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) - Insider Monkey
(RIGL) Long Term Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada
Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com
High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com
Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World
Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com
Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq
Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World
Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance
Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider
Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
Wall Street Analysts See a 71.97% Upside in Rigel (RIGL): Can the Stock Really Move This High? - sharewise
Rigel to Present at the Jefferies Global Healthcare Conference | RIGL Stock News - GuruFocus
Rigel to Present at the Jefferies Global Healthcare Conference – Company Announcement - Financial Times
Rigel Pharmaceuticals’ SWOT analysis: stock performance and pipeline potential By Investing.com - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: stock performance and pipeline potential - Investing.com
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Acquired by Northern Trust Corp - Defense World
BNP Paribas Financial Markets Grows Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals Approves Equity Plan Amendment - TipRanks
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):